Adoptive transfer of lymphocytes expressing engineered T cell receptors (TCR) is a promising option for cancer treatment and could include hepatocellularcarcinoma (HCC), where therapeutic options are limited. We have recently investigated whether hepatitis B viral antigens can act as a HCC-specific antigen and thus be targeted by adoptively transferred HBV-specific TCR redirected T cells.
Keywords: CHB, Chronic hepatitis B; HBV; SCID, Severe combined immunodeficiency; T cell therapy; hepatocellularcarcinoma.